NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

8 rGBM patients were not part of the 51 informational arm.

"A second cohort of patients with rGBM consisted of 8 patients with recurrence following several adjuvant temozolomide treatment cycles. Median OS for these patients is 14.7 months from the time of surgery for first recurrence."

These patients were not listed in the 51. Okay so that is out of the way.

No, that is not "out of the way"

Read the abstract.

"Nineteen (19) patients diagnosed with GBM were determined to have rapid recurrence following ....... Median overall survival in this cohort from initial GBM diagnosis is 15.1 months..."

I never claimed the 8 were part of the 51, these above 19 were part of the 51. And for them, survival was measured from initial GBM diagnosis.

As it was measured for the remaining patients in the poster. And if you want to compare this group with the ICT107 group, you need to subtract 13 weeks (I was wrong when I said 4 months, in their P2 it was 13 weeks between surgery and randomization).

Now I do not know if the rest of those were taken from diagnosis. If anything, that would be a very difficult measure, since they would have to get that information from the patient.

As noted above, it most definitely is from diagnosis. Surgical diagnosis. That's the only way to confirm GBM (the pathologist makes the diagnosis). And it's is a very easy date to nail down considering that to be in the INFO arm, you needed to have surgery at a trial site and signed the consent for tumor collection.

AVII, You were wrong about the medianOS of the 51 being 14 months. Just sayin'

It was 14.75 months from the time of Baseline (in the ICT107 trial which was 13 weeks after surgery).

From the NWBO press release:

"According to initial analyses, the median Overall Survival for all 55 patients is 18 months"

And that 18 months is from surgery.

subtract 13 weeks and you get 14.75 months from the corresponding randomization time for ICT-107 group you are trying to compare with.